Drugs / UCMSC-Exo
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06245746 | Feb 2025 → Feb 2026 overdue | acute myeloid leukemia, anemia, hemorrhagic disease, infectious disease +2 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06896747 | Feb → Jun 2025 overdue | adhesions of uterus, female infertility | Tang-Du Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCMSC-Exo | “Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning.” NCT06896747 ↗ |
| Known as | umbilical cord derived mesenchymal stem cells exosomes | “umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)” NCT06245746 ↗ |
| Action | Restore | “promote the repairment and regeneration of key cells such as hematopoietic stem cells, mesenchymal stem cells and endothelial cells” NCT06245746 ↗ |
| Modality | Other / unclassified | “umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)” NCT06245746 ↗ |
| Route | Intravenous | “UCMSC-Exo will be infused intravenously.” NCT06245746 ↗ |